TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

By

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer

By

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

By

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

By

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

By

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

By

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

By

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

By

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

By

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

By